Toxic Epidermal Necrolysis
Information
- Disease name
- Toxic Epidermal Necrolysis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01696500 | Completed | Phase 3 | Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | October 2012 | June 2014 |
| NCT03585946 | Not yet recruiting | Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | January 1, 2024 | December 31, 2028 | |
| NCT04711200 | Not yet recruiting | Phase 1/Phase 2 | LYell SYndrome MEsenchymal Stromal Cells Treatment | September 2022 | September 2025 |
| NCT06119490 | Recruiting | Early Phase 1 | Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis | July 5, 2023 | September 2026 |
| NCT02037347 | Terminated | Phase 1/Phase 2 | Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis | October 2010 | December 2014 |
| NCT02574988 | Unknown status | Severe Cutaneous Adverse Reactions in Thailand | January 2014 | December 2020 | |
| NCT02795143 | Withdrawn | N/A | Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study | November 2016 | June 2020 |
| NCT00372723 | Withdrawn | Phase 2 | Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) | July 2006 | June 2011 |
| NCT02319616 | Withdrawn | Phase 1/Phase 2 | Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis | November 2016 | February 6, 2019 |
- OrphaNumber from OrphaNet (Orphanet)
- 537